SPONSOR
The Lymphoma Academic Research Organisation
Total Trials
3
Recruiting
3
Phases
Phase 2, Phase 1, Phase 2
Conditions studied: Diffuse Large B-cell Lymphoma RefractoryRefractory Primary Mediastinal Large B-Cell LymphomaRefractory Transformed B-cell Non-Hodgkin LymphomaRefractory High Grade B-Cell LymphomaPeripheral T Cells Lymphoma (PTCL)Primary CNS Lymphoma (PCNSL)
The Lymphoma Academic Research Organisation is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma.
The trial portfolio spans Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The Lymphoma Academic Research Organisation
How many clinical trials has The Lymphoma Academic Research Organisation sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by The Lymphoma Academic Research Organisation, of which 3 are actively recruiting participants. These trials cover conditions including Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The Lymphoma Academic Research Organisation research focus on?
The Lymphoma Academic Research Organisation clinical trials span Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma, Peripheral T Cells Lymphoma (PTCL), and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The Lymphoma Academic Research Organisation clinical trial?
To participate in a The Lymphoma Academic Research Organisation trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The Lymphoma Academic Research Organisation trials with current recruitment status updated daily.
Clinical Trials by The Lymphoma Academic Research Organisation
NCT06271057 Phase 2
Recruiting
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Diffuse Large B-cell Lymphoma Refractory
NCT07018752 Phase 1, Phase 2
Recruiting
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Peripheral T Cells Lymphoma (PTCL)
NCT06931652 Phase 2
Recruiting
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Primary CNS Lymphoma (PCNSL)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology